INVESTING IN THE INFRASTRUCTURE OF TOMORROW'S MEDICINES

Overview

Compugen is a drug discovery company with a unique, broadly applicable, predictive discovery infrastructure, which is advancing a therapeutic pipeline consisting mainly of early-stage immuno-oncology programs, aimed at harnessing the immune system to eradicate cancer. Our pipeline is based on novel Compugen-discovered drug targets, primarily immune checkpoint candidates that are predicted to provide cancer immunotherapies addressing unmet cancer types and patient populations, both as monotherapy and in combination.
Read more …

Investors Highlights

MORE PRESS RELEASES

CGEN Stock Quote

NASDAQ

5.30 +0.25 (+4.95%)
CGEN on NASDAQ website >

TASE

1833.00 +104.00 (+6.02%)
CGEN on Tel- Aviv Stock Exchange website >
Quotes are delayed by 20 minutes at least

Annual and Quarterly Reports

MORE REPORTS
Jun 05, 2017

Compugen to Present at 2017 ASCO

Chicago, Illinois
May 14, 2017

Compugen to Present at IMMUNOLOGY 2017

Washington, DC
Apr 02, 2017

Compugen to Present at AACR 2017

Washington, DC
MORE EVENTS